Cargando…

Molecular features of early onset adult myelodysplastic syndrome

Myelodysplastic syndromes are typically diseases of older adults. Patients in whom the onset is early may have distinct molecular and clinical features or reflect a demographic continuum. The identification of differences between “early onset” patients and those diagnosed at a traditional age has th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirsch, Cassandra M., Przychodzen, Bartlomiej P., Radivoyevitch, Tomas, Patel, Bhumika, Thota, Swapna, Clemente, Michael J., Nagata, Yasunobu, LaFramboise, Thomas, Carraway, Hetty E., Nazha, Aziz, Sekeres, Mikkael A., Makishima, Hideki, Maciejewski, Jaroslaw P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451334/
https://www.ncbi.nlm.nih.gov/pubmed/28255022
http://dx.doi.org/10.3324/haematol.2016.159772
Descripción
Sumario:Myelodysplastic syndromes are typically diseases of older adults. Patients in whom the onset is early may have distinct molecular and clinical features or reflect a demographic continuum. The identification of differences between “early onset” patients and those diagnosed at a traditional age has the potential to advance understanding of the pathogenesis of myelodysplasia and may lead to formation of distinct morphological subcategories. We studied a cohort of 634 patients with various subcategories of myelodysplastic syndrome and secondary acute myeloid leukemia, stratifying them based on age at presentation and clinical parameters. We then characterized molecular abnormalities detected by next-generation deep sequencing of 60 genes that are commonly mutated in myeloid malignancies. The number of mutations increased linearly with age and on average, patients >50 years of age had more mutations. TET2, SRSF2, and DNMT3A were more commonly mutated in patients >50 years old compared to patients ≤50 years old. In general, patients >50 years of age also had more mutations in spliceosomal, epigenetic modifier, and RAS gene families. Although there are age-related differences in molecular features among patients with myelodysplasia, most notably in the incidence of SRSF2 mutations, our results suggest that patients ≤50 years old belong to a disease continuum with a distinct pattern of early onset ancestral events.